Gå direkt till innehåll
Vicore Pharma strengthens its management team

Pressmeddelande -

Vicore Pharma strengthens its management team

..............................................................

GU Ventures sprider nyheter och information kring verksamheten, sina bolag, samt alumnibolag

resterande pressmeddelande följer på engelska:
..............................................................

Vicore Pharma Holding AB, a rare disease pharmaceutical company developing innovative medicines for fibrotic lung disorders such as idiopathic pulmonary fibrosis (IPF), today announces the addition of three experienced executives to its management team, strengthening business and commercial operations as the company’s research and development activities approach key commercial decision points.

Åsa Magnusson will join as Vicore’s Chief Commercial Officer and Mikael Nygård will join as VP of Business Development, becoming part of an enlarged management team. Jessica Shull, recently recruited Head of Digital Therapeutics will also join the Vicore management.

Åsa Magnusson will take responsibility for the company’s commercialization activities. She has more than 20 years of experience as a commercial executive in the pharmaceutical industry with focus on securing market access and launching rare disease medicines in areas with a high unmet medical need. She joins Vicore from Arvelle Therapeutics - a CNS and epilepsy focused biotech company based in Switzerland. Previously, Åsa worked in different international and Nordic commercial roles at Alexion, expanding innovative antibody products such as Soliris and Ultomiris. Before that, she headed the marketing of Actelion’s pulmonary arterial hypertension (PAH) pharmaceuticals, including launching Opsumit and new indications for Tracleer in the Nordic territories. Åsa will take up her role with Vicore in October 2021.

Mikael Nygård will take responsibility for the company’s business development activities, including partnering, licensing and M&A. Mikael comes with extensive experience in the healthcare industry, most recently as Head of M&A and Corporate Development at the care provider Humana AB. At Humana, Mikael has held various positions, and in his most recent role he oversaw several acquisitions and was involved in developing and implementing the company’s growth strategy. Before that, he worked in the global healthcare team at the strategy consulting firm Boston Consulting Group. Mikael holds a PhD in Neuroscience from Karolinska Institutet. Mikael will take up his role in Vicore in November 2021.

Jessica Shull joined Vicore in May 2021 to oversee the development and launch of the VP04 digital therapeutic program in IPF. Before joining Vicore, Jessica gained more than 20 years’ experience in the field of digital technologies for healthcare including development of virtual surgical devices. She is considered an authority in HTA requirements for patient-facing software and innovation adoption in Europe and abroad. In previous roles she worked on digital health best practices for the WHO and with the Digital Therapeutics Alliance she focused on digital health recognition, regulation, and policy.

Åsa Magnusson, Mikael Nygård and Jessica Shull will all join the expanded Vicore management team.


“At Vicore we are forging a powerful expanded team with a huge collective experience. As our programs in IPF and COVID-19 progress towards significant value-creating clinical milestones, we are putting in place a diligent and agile leadership with the capabilities necessary to respond to the challenges of a fast moving and evolving healthcare market.“ says Carl-Johan Dalsgaard, CEO of Vicore.

Ämnen

Kategorier

Regioner



About GU Ventures AB

GU Ventures builds businesses out of groundbreaking ideas that help shape a better tomorrow and is top-ranked by UBI Global Index as one of the world's 20 leading university-run incubators. We finance and develop new innovative business ideas with connections to the University of Gothenburg, which is one of northern Europe's largest universities. Our mission is commercialize the innovations, which leads to the utilization of research and skills, renewal of the business community, job creation and sustainable growth. Our passionate team of company builders, financial experts, IP and legal talent are dedicated supporters of our companies and ensure their successes. Since our starting point in 1995, GU Ventures has developed over 200 new business ideas of which 130 are in business today and of which 14 are listed. Our portfolio consists of 70 holdings and some projects. In the latest survey, 87% of companies match the global sustainability goals set by the UN. GU Ventures is wholly owned by the Swedish state and managed by the University of Gothenburg. Feel free to read more at: www.guventures.com.

Kontakter

Relaterat innehåll

  • Vicore Pharma har tagit in 336 Mkr i en riktad nyemission

    Vicore Pharma har tagit in 336 Mkr i en riktad nyemission

    Vicore Pharma offentliggör att Bolaget framgångsrikt genomfört en riktad nyemission av 11 200 000 aktier, motsvarande 336 miljoner kronor. Teckningskursen i den Riktade Nyemissionen bestämdes till 30,0 SEK per aktie och tecknades av svenska och internationella institutionella investerare samt vissa befintliga aktieägare, däribland Fjärde AP-fonden, Handelsbanken Fonder, HBM Healthcare Investments

  • Vicore Pharma rapporterar positiva resultat från ATTRACT-studien i patienter med COVID-19

    Vicore Pharma rapporterar positiva resultat från ATTRACT-studien i patienter med COVID-19

    ​Oral C21-behandling visar en signifikant klinisk förbättring i tillägg till kortikosteroider. Vicore Pharma Holding AB (publ), som utvecklar innovativa läkemedel mot allvarliga lungsjukdomar, meddelar idag positiva "top line"-resultat från ATTRACTstudien med C21 (VP01) i COVID-19. En webbsändning kommer att hållas i eftermiddag kl 15:00 CET (09:00 EST).

  • Vicore obtains SARS coronavirus patent for C21 in the USA

    Vicore obtains SARS coronavirus patent for C21 in the USA

    Vicore Pharma Holding AB (publ) (“Vicore”), a rare disease pharmaceutical company developing innovative medicines for severe lung disorders, today announces that the U.S. Patent and Trademark Office (USPTO) has granted patent number US11,123,329 covering the use of C21 to treat infections caused by Severe Acute Respiratory Syndrome (SARS) coronavirus (CoV), including SARS-CoV-2.